Boston & Munich– Wacker Biotech, a leading contract development and manufacturing organization (CDMO) under Wacker Chemie AG, has announced a strategic collaboration with Boston-based RNAV8 Bio to enhance the development and production of mRNA-based therapies.
The partnership leverages Wacker Biotech’s expertise in plasmid DNA (pDNA) and mRNA manufacturing, including lipid nanoparticle (LNP) formulation, alongside RNAV8 Bio’s proprietary mRNA engineering platform. RNAV8 specializes in optimizing untranslated regions (UTRs) of mRNA sequences, which play a critical role in drug stability, transport, and efficacy.
“As mRNA therapeutics expand into broader applications, optimizing mRNA expression is key to improving efficacy and reducing required dosages,” said Devan Shah, CEO of RNAV8 Bio. “With Wacker Biotech’s proven manufacturing capabilities, this collaboration enables us to deliver highly efficient mRNA therapeutics at scale.”
Philippe Cronet, General Manager of Wacker Biotech US Inc., emphasized the impact of the partnership: “Together with RNAV8, we offer a cutting-edge solution for drug developers, enabling rapid prototyping, optimization, and scale-up of mRNA therapeutics. This collaboration strengthens our position as a premier mRNA manufacturing and development service provider.”
Wacker Biotech operates GMP-certified facilities across Germany, the Netherlands, and the U.S., specializing in microbial fermentation and nucleic acid production. RNAV8 Bio applies AI-driven mRNA design strategies to enhance therapeutic performance, securing collaborations with major biotech and pharmaceutical firms.
This strategic alliance aims to meet the increasing demand for advanced mRNA therapies, offering an integrated approach to optimize drug development and production.
Wacker Biotech provides contract manufacturing services for therapeutic proteins, live microbial products (LMPs), pDNA, mRNA, and vaccines. Its GMP-compliant facilities in Germany, the Netherlands, and the U.S. support clinical and commercial production.
RNAV8 Bio combines machine learning and AI with rational mRNA design to enhance drug performance. The company’s technology optimizes mRNA function, improving therapeutic efficacy and durability.
